NCT04350177View on ClinicalTrials.gov

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

February 16, 2021

Primary Completion Date

October 30, 2022

Study Completion Date

January 30, 2023

Conditions
Healthy ElderlyParkinson Disease
Interventions
DRUG

IkT-148009

Oral administration gelatin capsule

DRUG

Placebo

Oral administration gelatin capsule

Trial Locations (4)

33009

Velocity Clinical Research, Hallandale

48334

Quest Research Institute LLC, Farmington Hills

90806

Collaborative Neuroscience Research, LLC, Long Beach

08053

Hassman Research Institute, Marlton

Sponsors
All Listed Sponsors
lead

ABLi Therapeutics, Inc.

INDUSTRY